Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 438 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: coagulation study Clear all
Completed Phase 1 Interventional

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

NCT01845428
View directory record Official record
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Pravastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 23, 2026, 10:44 AM EDT
Withdrawn Phase 3 Interventional

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B

NCT02048111
View directory record Official record
Conditions
Hemophilia B
Interventions
IB1001
Biological
Lead sponsor
Cangene Corporation
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 23, 2026, 10:44 AM EDT
Recruiting Phase 2 Interventional

Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

NCT07136857
View directory record Official record
Conditions
Glanzmann Thrombasthenia
Interventions
EPTACOG BETA
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

NCT01775618
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
Up to 12 Years · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
7
States / cities
Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

NCT00073593
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Surgery
Interventions
Bivalirudin, Heparin, Protamine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Oct 23, 2026, 10:44 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

NCT03295981
View directory record Official record
Conditions
Giant Cell Tumor of Bone
Interventions
Zoledronic Acid
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
14
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 10:44 AM EDT
Terminated Phase 2 Interventional Results available

Anticoagulation For Pulmonary Hypertension in Sickle Cell Disease

NCT01036802
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Warfarin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD

NCT00752557
View directory record Official record
Conditions
Osteoporosis
Interventions
rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy), bisphosphonates, calcium, and vitamin D
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)

NCT00586521
View directory record Official record
Conditions
Hematologic Disease, Hemophilia A
Interventions
Kogenate (BAY14-2222)
Drug
Lead sponsor
Bayer
Industry
Eligibility
30 Years to 45 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Oct 23, 2026, 10:44 AM EDT
Active, not recruiting Not applicable Interventional

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

NCT07597239
View directory record Official record
Conditions
Thrombosis, Arterial Occlusive Diseases, Thromboelastography (TEG), Peripheral Arterial Disease(PAD), Stent Thrombosis, Platelet Inhibition, PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Platelet Reactivity Testing, Thromboelastography with Platelet Mapping
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

NCT02083965
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Salt Lake City, Utah • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 10:44 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
D. Walter Wray
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 10:44 AM EDT
Terminated Phase 2 Interventional Results available

Alphanate in Immune Tolerance Induction Therapy

NCT03095287
View directory record Official record
Conditions
Hemophilia A, Congenital
Interventions
Alphanate
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
Up to 12 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Atlanta, Georgia • Lexington, Kentucky • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 23, 2026, 10:44 AM EDT
Recruiting Phase 1 Interventional

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05723107
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Chemotherapy, Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures

NCT02548143
View directory record Official record
Conditions
Hemophilia
Interventions
Coagulation Factor VIIa (Recombinant)
Biological
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Industry
Eligibility
6 Months to 75 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 23, 2026, 10:44 AM EDT
Completed No phase listed Observational

ATHN 7: Hemophilia Natural History Study

NCT03619863
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Haemophilia A Without Inhibitor, Hemophilia B With Inhibitor, Haemophilia B Without Inhibitor
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 23, 2026, 10:44 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

NCT01998828
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocythemia
Interventions
Momelotinib
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Whittier, California • Tupelo, Mississippi + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 3 Interventional Results available

Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.

NCT02740335
View directory record Official record
Conditions
Significant Bleeding Risk
Interventions
Octaplex, Beriplex P/N (Kcentra)
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
22
States / cities
Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Platelets in Chronic HIV Infection

NCT02578706
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Clopidogrel, Aspirin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 4 Interventional Results available

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

NCT00243386
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
7 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 23, 2026, 10:44 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

NCT00439972
View directory record Official record
Conditions
Contraception
Interventions
Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 14, 2011 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture

NCT02207205
View directory record Official record
Conditions
Healthy
Interventions
Blood drawn from indwelling catheters versus direct venipuncture
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 2Phase 3 Interventional

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

NCT01625390
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
BAY86-6150, eptacog alfa [activated]
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 62 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Sacramento, California • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Oct 23, 2026, 10:44 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

NUTRITION: Natural Tocotrienol Against Ischemic Stroke Event

NCT01578629
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack (TIA)
Interventions
Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin, Placebo vehicle control
Other
Lead sponsor
Andrew Slivka
Other
Eligibility
40 Years to 70 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 23, 2026, 10:44 AM EDT